Search

Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

Bevirimat

They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein. … Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid.

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Nitric acid

Friulimicin B

It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.

Dovitinib

Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis.

Triacetin

Phenolsulfonphthalein

Phenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories.

Veligrotug

[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]